sodium-bicarbonate and Atrial-Fibrillation

sodium-bicarbonate has been researched along with Atrial-Fibrillation* in 3 studies

Reviews

1 review(s) available for sodium-bicarbonate and Atrial-Fibrillation

ArticleYear
Sodium bicarbonate in the prevention of cardiac surgery-associated acute kidney injury: a systematic review and meta-analysis.
    Critical care (London, England), 2014, Sep-12, Volume: 18, Issue:5

    Sodium bicarbonate (SBIC) was reported to be a promising approach to prevent cardiac surgery-associated acute kidney injury (CSA-AKI). However, the results remain controversial. We conducted a systematic review and meta-analysis to evaluate the efficacy and safety of SBIC on the prevention of CSA-AKI in adult patients undergoing cardiac surgery.. PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases were systematically searched. Randomized controlled trials (RCTs) assessing the effect of SBIC versus placebo on the prevention of CSA-AKI in adult patients undergoing cardiac surgery were included. Two investigators independently searched articles, extracted data, and assessed the quality of included studies. The primary outcome was the incidence of CSA-AKI. Meta-analysis was performed using random-effects models.. Five RCTs involving 1079 patients were included in the meta-analysis. Overall, compared with placebo, SBIC was not associated with a reduced risk of CSA-AKI (relative risk [RR] 0.99; 95% confidence interval [CI] 0.78 to 1.24; P = 0.911). SBIC failed to alter the clinical outcomes of hospital length of stay (weighted mean difference [WMD] 0.23 days; 95%CI -0.88 to 1.33 days; P = 0.688), renal replacement therapy (RR 0.94; 95%CI 0.49 to 1.82; P = 0.861), hospital mortality (RR 1.37; 95%CI 0.46 to 4.13; P = 0.572), postoperative atrial fibrillation (RR 1.02; 95%CI 0.65 to 1.61; P = 0.915). However, SBIC was associated with significant increased risks in longer duration of ventilation (WMD 0.64 hours; 95%CI 0.16 to 1.11 hours; P = 0.008), longer ICU length of stay (WMD 2.06 days; 95%CI 0.54 to 3.58 days; P = 0.008), and increased incidence of alkalemia (RR 2.21; 95%CI 1.42 to 3.42; P <0.001).. SBIC could not reduce the incidence of CSA-AKI. Contrarily, SBIC prolongs the duration of ventilation and ICU length of stay, and increases the risk of alkalemia. Thus, SBIC should not be recommended for the prevention of CSA-AKI and perioperative SBIC infusion should be administrated with caution.

    Topics: Acute Kidney Injury; Adult; Atrial Fibrillation; Cardiac Surgical Procedures; Humans; Length of Stay; Postoperative Complications; Randomized Controlled Trials as Topic; Renal Replacement Therapy; Sodium Bicarbonate

2014

Other Studies

2 other study(ies) available for sodium-bicarbonate and Atrial-Fibrillation

ArticleYear
ECG of the month. Atrial fibrillation due to hypokalemia in a horse.
    Journal of the American Veterinary Medical Association, 2014, Mar-15, Volume: 244, Issue:6

    Topics: Acidosis; Animals; Atrial Fibrillation; Boric Acids; Crystalloid Solutions; Electrocardiography; Female; Horse Diseases; Horses; Hypokalemia; Isotonic Solutions; Potassium Chloride; Sodium Bicarbonate

2014
Iatrogenic Flecainide toxicity.
    Heart (British Cardiac Society), 2010, Volume: 96, Issue:24

    Topics: Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Confusion; Female; Flecainide; Hallucinations; Humans; Shock; Sodium Bicarbonate

2010